Other Events ·
Securities class action lawsuit filed against Unicycive Therapeutics over statements regarding new drug application
UNCYUnicycive Therapeutics, Inc.
On September 3, 2026, a securities class action lawsuit was filed in the United States District Court for the Northern District of California against Unicycive Therapeutics, Inc. and certain officers. The complaint alleges violations of federal securities laws related to public statements concerning the company's new drug application for oxylanthanum carbonate phosphate binder, intended for treating hyperphosphatemia in chronic kidney disease patients on dialysis. The company asserts the claims are meritless and intends to vigorously defend against them. Unicycive Therapeutics operates in the biotechnology industry, focusing on developing therapies for metabolic bone diseases.